DeMarco Allan LLP Congratulates Antibe Therapeutics Inc. on Closing of Public Offering
August 21, 2017
DeMarco Allan LLP, with a team composed of Robert Eberschlag, John Carron and Jonathan McGillivray, acted as legal counsel to Antibe Therapeutics Inc., a diversified biotechnology company, in connection with Antibe's marketed public offering of units.
The offering, completed Friday, August 18, 2017, by way of a short-form prospectus, raised gross proceeds of approximately $5 million. Bloom Burton Securities Inc., Dominick Inc. and Echelon Wealth Partners Inc. acted as co-agents in connection with the brokered offering. Antibe is listed on the TSX Venture Exchange under the symbol "ATE".